je.st
news
Home
› Lexicon and Ipsen enter into ex-North America/Japan licensing and commercialization agreement for telotristat etiprate
Lexicon and Ipsen enter into ex-North America/Japan licensing and commercialization agreement for telotristat etiprate
2014-10-22 15:11:12| Biotech - Topix.net
Ipsen and Lexicon Pharmaceuticals, Inc. today announced that they have entered into an exclusive licensing agreement for Ipsen to commercialize telotristat etiprate outside of North America and Japan, with a focus on the treatment of carcinoid syndrome. Lexicon retains sole rights to commercialize telotristat etiprate in the United States, Canada and Japan.
Tags: enter
agreement
licensing
lexicon
Category:Biotechnology and Pharmaceuticals